Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212361 | 0.96 | CAPN1 (0.31) | CAPN1TSHRCTSLLMNACTSB | |
| SCHEMBL19220858 | 0.96 | CAPN1 (0.31) | CAPN1TSHRCTSLLMNACTSB | |
| SCHEMBL19220866 | 0.96 | CAPN1 (0.31) | CAPN1TSHRCTSLLMNACTSB | |
| SCHEMBL19276559 | 0.84 | ADORA3 (0.34) | TSHRHSP90B1 | |
| SCHEMBL19276557 | 0.84 | ADORA3 (0.34) | TSHRHSP90B1 | |
| SCHEMBL19276558 | 0.84 | ADORA3 (0.34) | TSHRHSP90B1 | |
| SCHEMBL14212364 | 0.77 | ADORA3 (0.33) | TSHRLMNAHSP90B1 | |
| SCHEMBL19220862 | 0.77 | ADORA3 (0.33) | TSHRLMNAHSP90B1 | |
| SCHEMBL19220863 | 0.77 | ADORA3 (0.33) | TSHRLMNAHSP90B1 | |
| SCHEMBL14212357 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324793-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324793-A1 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY | ALG1, CD44, CD47 | CAPN1 676/4885TSHR 4751/4885CTSL 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.